Search research articles
Contact Us
Filters
Showing results (91-100 of 111) with videos related to
Page
of 12
Sort By:
Annals of Neurology
|
December 16, 1998
Susceptibility to multiple sclerosis and the immunoglobulin heavy chain gene cluster
R Feakes, J Chataway, S Sawcer, et al.
Genetic Epidemiology
|
January 1, 1997
Empirical genomewide significance levels established by whole genome simulations
S Sawcer, H B Jones, D Judge, et al.
Osteoarthritis and Cartilage
|
December 31, 2008
Cellular and histopathological changes in the infrapatellar fat pad in the monoiodoacetate model of osteoarthritis pain
K M Clements, A D Ball, H B Jones, et al.
Neurotoxicology
|
January 1, 1996
Neuropathological changes in rat brain following oral administration of 2-chloropropionic acid
M G Simpson, I Wyatt, H B Jones, et al.
Urological Research
|
January 1, 1994
Pathological and morphometric assessment of testicular parameters in patients with metastatic prostate cancer following treatment with either the antiandrogen Casodex (ZM176,334) or bilateral orchidectomy
H B Jones, G R Betton, A L Bowdler, et al.
Toxicologic Pathology
|
April 12, 2012
Evaluation of novel renal biomarkers with a cisplatin model of kidney injury: gender and dosage differences
M Pinches, C Betts, S Bickerton, et al.
Neuropathology and Applied Neurobiology
|
July 1, 1984
Evolution of the intracellular changes in neurons caused by trimethyltin
A W Brown, J B Cavanagh, R D Verschoyle, et al.
Cancer Biomarkers : Section a of Disease Markers
|
December 29, 2006
Current status and future directions for diagnostic markers of drug-induced vascular injury
D A Brott, H B Jones, S Gould, et al.
FEMS Immunology and Medical Microbiology
|
January 21, 2000
Characterisation of Candida albicans infections of haematogenous and mucosal origin in mice lacking the interferon gamma receptor protein
L P Londono, H B Jones, A T Vie, et al.
British Journal of Pharmacology
|
April 29, 2014
Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes
D J Baker, G P Wilkinson, A M Atkinson, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 111) with videos related to
Sort By:
Page
of 12
Annals of Neurology
|
December 16, 1998
Susceptibility to multiple sclerosis and the immunoglobulin heavy chain gene cluster
R Feakes, J Chataway, S Sawcer, et al.
Genetic Epidemiology
|
January 1, 1997
Empirical genomewide significance levels established by whole genome simulations
S Sawcer, H B Jones, D Judge, et al.
Osteoarthritis and Cartilage
|
December 31, 2008
Cellular and histopathological changes in the infrapatellar fat pad in the monoiodoacetate model of osteoarthritis pain
K M Clements, A D Ball, H B Jones, et al.
Neurotoxicology
|
January 1, 1996
Neuropathological changes in rat brain following oral administration of 2-chloropropionic acid
M G Simpson, I Wyatt, H B Jones, et al.
Urological Research
|
January 1, 1994
Pathological and morphometric assessment of testicular parameters in patients with metastatic prostate cancer following treatment with either the antiandrogen Casodex (ZM176,334) or bilateral orchidectomy
H B Jones, G R Betton, A L Bowdler, et al.
Toxicologic Pathology
|
April 12, 2012
Evaluation of novel renal biomarkers with a cisplatin model of kidney injury: gender and dosage differences
M Pinches, C Betts, S Bickerton, et al.
Neuropathology and Applied Neurobiology
|
July 1, 1984
Evolution of the intracellular changes in neurons caused by trimethyltin
A W Brown, J B Cavanagh, R D Verschoyle, et al.
Cancer Biomarkers : Section a of Disease Markers
|
December 29, 2006
Current status and future directions for diagnostic markers of drug-induced vascular injury
D A Brott, H B Jones, S Gould, et al.
FEMS Immunology and Medical Microbiology
|
January 21, 2000
Characterisation of Candida albicans infections of haematogenous and mucosal origin in mice lacking the interferon gamma receptor protein
L P Londono, H B Jones, A T Vie, et al.
British Journal of Pharmacology
|
April 29, 2014
Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes
D J Baker, G P Wilkinson, A M Atkinson, et al.
Page
of 12